319 related articles for article (PubMed ID: 32223429)
1. The Effect of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition on the Risk of Venous Thromboembolism.
Marston NA; Gurmu Y; Melloni GEM; Bonaca M; Gencer B; Sever PS; Pedersen TR; Keech AC; Roselli C; Lubitz SA; Ellinor PT; O'Donoghue ML; Giugliano RP; Ruff CT; Sabatine MS
Circulation; 2020 May; 141(20):1600-1607. PubMed ID: 32223429
[TBL] [Abstract][Full Text] [Related]
2. Peripheral Artery Disease and Venous Thromboembolic Events After Acute Coronary Syndrome: Role of Lipoprotein(a) and Modification by Alirocumab: Prespecified Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial.
Schwartz GG; Steg PG; Szarek M; Bittner VA; Diaz R; Goodman SG; Kim YU; Jukema JW; Pordy R; Roe MT; White HD; Bhatt DL;
Circulation; 2020 May; 141(20):1608-1617. PubMed ID: 32223446
[TBL] [Abstract][Full Text] [Related]
3. Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk).
Bonaca MP; Nault P; Giugliano RP; Keech AC; Pineda AL; Kanevsky E; Kuder J; Murphy SA; Jukema JW; Lewis BS; Tokgozoglu L; Somaratne R; Sever PS; Pedersen TR; Sabatine MS
Circulation; 2018 Jan; 137(4):338-350. PubMed ID: 29133605
[TBL] [Abstract][Full Text] [Related]
4. Lipoprotein(a) reductions from PCSK9 inhibition and major adverse cardiovascular events: Pooled analysis of alirocumab phase 3 trials.
Ray KK; Vallejo-Vaz AJ; Ginsberg HN; Davidson MH; Louie MJ; Bujas-Bobanovic M; Minini P; Eckel RH; Cannon CP
Atherosclerosis; 2019 Sep; 288():194-202. PubMed ID: 31253441
[TBL] [Abstract][Full Text] [Related]
5. Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk.
O'Donoghue ML; Fazio S; Giugliano RP; Stroes ESG; Kanevsky E; Gouni-Berthold I; Im K; Lira Pineda A; Wasserman SM; Češka R; Ezhov MV; Jukema JW; Jensen HK; Tokgözoğlu SL; Mach F; Huber K; Sever PS; Keech AC; Pedersen TR; Sabatine MS
Circulation; 2019 Mar; 139(12):1483-1492. PubMed ID: 30586750
[TBL] [Abstract][Full Text] [Related]
6. Inflammatory and Cholesterol Risk in the FOURIER Trial.
Bohula EA; Giugliano RP; Leiter LA; Verma S; Park JG; Sever PS; Lira Pineda A; Honarpour N; Wang H; Murphy SA; Keech A; Pedersen TR; Sabatine MS
Circulation; 2018 Jul; 138(2):131-140. PubMed ID: 29530884
[TBL] [Abstract][Full Text] [Related]
7. Clinical Benefit of Evolocumab by Severity and Extent of Coronary Artery Disease: Analysis From FOURIER.
Sabatine MS; De Ferrari GM; Giugliano RP; Huber K; Lewis BS; Ferreira J; Kuder JF; Murphy SA; Wiviott SD; Kurtz CE; Honarpour N; Keech AC; Sever PS; Pedersen TR
Circulation; 2018 Aug; 138(8):756-766. PubMed ID: 29626068
[TBL] [Abstract][Full Text] [Related]
8. Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes.
Roe MT; Li QH; Bhatt DL; Bittner VA; Diaz R; Goodman SG; Harrington RA; Jukema JW; Lopez-Jaramillo P; Lopes RD; Louie MJ; Moriarty PM; Szarek M; Vogel R; White HD; Zeiher AM; Baccara-Dinet MT; Steg PG; Schwartz GG
Circulation; 2019 Nov; 140(19):1578-1589. PubMed ID: 31475572
[TBL] [Abstract][Full Text] [Related]
9. PCSK9 Inhibitors in Secondary Prevention-An Opportunity for Personalized Therapy.
Board C; Kelly MS; Shapiro MD; Dixon DL
J Cardiovasc Pharmacol; 2020 May; 75(5):410-420. PubMed ID: 32379108
[TBL] [Abstract][Full Text] [Related]
10. From lipoprotein apheresis to proprotein convertase subtilisin/kexin type 9 inhibitors: Impact on low-density lipoprotein cholesterol and C-reactive protein levels in cardiovascular disease patients.
Zenti MG; Altomari A; Lupo MG; Botta M; Bonora E; Corsini A; Ruscica M; Ferri N
Eur J Prev Cardiol; 2018 Nov; 25(17):1843-1851. PubMed ID: 30058841
[TBL] [Abstract][Full Text] [Related]
11. Residual Inflammatory Risk on Treatment With PCSK9 Inhibition and Statin Therapy.
Pradhan AD; Aday AW; Rose LM; Ridker PM
Circulation; 2018 Jul; 138(2):141-149. PubMed ID: 29716940
[TBL] [Abstract][Full Text] [Related]
12. An Exploratory Analysis of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition and Aortic Stenosis in the FOURIER Trial.
Bergmark BA; O'Donoghue ML; Murphy SA; Kuder JF; Ezhov MV; Ceška R; Gouni-Berthold I; Jensen HK; Tokgozoglu SL; Mach F; Huber K; Gaciong Z; Lewis BS; Schiele F; Jukema JW; Pedersen TR; Giugliano RP; Sabatine MS
JAMA Cardiol; 2020 Jun; 5(6):709-713. PubMed ID: 32347887
[TBL] [Abstract][Full Text] [Related]
13. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
Yadav K; Sharma M; Ferdinand KC
Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
[TBL] [Abstract][Full Text] [Related]
14. Changes in circulating pro-protein convertase subtilisin/kexin type 9 levels - experimental and clinical approaches with lipid-lowering agents.
Macchi C; Banach M; Corsini A; Sirtori CR; Ferri N; Ruscica M
Eur J Prev Cardiol; 2019 Jun; 26(9):930-949. PubMed ID: 30776916
[TBL] [Abstract][Full Text] [Related]
15. PCSK9 Inhibitors: Mechanism of Action, Efficacy, and Safety.
Roth EM; Davidson MH
Rev Cardiovasc Med; 2018; 19(S1):S31-S46. PubMed ID: 30207556
[TBL] [Abstract][Full Text] [Related]
16. Lipoprotein(a) Reduction With Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic Review and Meta-analysis.
Farmakis I; Doundoulakis I; Pagiantza A; Zafeiropoulos S; Antza C; Karvounis H; Giannakoulas G
J Cardiovasc Pharmacol; 2021 Mar; 77(3):397-407. PubMed ID: 33298738
[TBL] [Abstract][Full Text] [Related]
17. Real-world data on metabolic effects of PCSK9 inhibitors in a tertiary care center in patients with and without diabetes mellitus.
Fischer LT; Hochfellner DA; Knoll L; Pöttler T; Mader JK; Aberer F
Cardiovasc Diabetol; 2021 Apr; 20(1):89. PubMed ID: 33894772
[TBL] [Abstract][Full Text] [Related]
18. Alirocumab therapy in individuals with type 2 diabetes mellitus and atherosclerotic cardiovascular disease: analysis of the ODYSSEY DM-DYSLIPIDEMIA and DM-INSULIN studies.
Ray KK; Del Prato S; Müller-Wieland D; Cariou B; Colhoun HM; Tinahones FJ; Domenger C; Letierce A; Mandel J; Samuel R; Bujas-Bobanovic M; Leiter LA
Cardiovasc Diabetol; 2019 Nov; 18(1):149. PubMed ID: 31706300
[TBL] [Abstract][Full Text] [Related]
19. PCSK9 Inhibitors in Lipid Management of Patients With Diabetes Mellitus and High Cardiovascular Risk: A Review.
Handelsman Y; Lepor NE
J Am Heart Assoc; 2018 Jun; 7(13):. PubMed ID: 29934421
[No Abstract] [Full Text] [Related]
20. Associations between lower levels of low-density lipoprotein cholesterol and cardiovascular events in very high-risk patients: Pooled analysis of nine ODYSSEY trials of alirocumab versus control.
Vallejo-Vaz AJ; Ray KK; Ginsberg HN; Davidson MH; Eckel RH; Lee LV; Bessac L; Pordy R; Letierce A; Cannon CP
Atherosclerosis; 2019 Sep; 288():85-93. PubMed ID: 31349086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]